TOKYO – An ongoing downturn in global trade may turn out to be unexpectedly severe, but in the midst of the ongoing difficulties there may be opportunities for biotech companies. That was the opinion of industry executives speaking at the Bio Asia International Conference last week, as they generally agreed that this year should be a good one for biotech stocks, in no small part thanks to an expected recovery from the sharp correction during the last quarter of 2018.
TOKYO – An ongoing downturn in global trade may turn out to be unexpectedly severe, but in the midst of the ongoing difficulties there may be opportunities for biotech companies. That was the opinion of industry executives speaking at the Bio Asia International Conference last week, as they generally agreed that this year should be a good one for biotech stocks, in no small part thanks to an expected recovery from the sharp correction during the last quarter of 2018.
TOKYO – Pharmaceutical companies are growing increasingly concerned about the knock-on effect of new legislation in Japan that changes how drugs are priced. Set to take effect in April, those reforms, which introduce new frameworks on cost-effectiveness, will also have repercussions on reimbursement guidelines for biotechnology innovations.
TOKYO – Defying the non-litigious nature of Japanese companies, makers of drugs and biosimilars are increasingly willing to file lawsuits to protect patents or clear the way to market biosimilars.
TOKYO – Defying the non-litigious nature of Japanese companies, makers of drugs and biosimilars are increasingly willing to file lawsuits to protect patents or clear the way to market biosimilars.
TOKYO – Japanese pharmaceutical companies are downsizing, bucking a longstanding practice in the country of providing lifetime employment, even as they try to prepare for the possibility of a shrinking industry.
TOKYO – Japanese pharmaceutical companies are downsizing, bucking a longstanding practice in the country of providing lifetime employment, even as they try to prepare for the possibility of a shrinking industry.
TOKYO – Japan's Taiho Oncology Inc. won U.S. FDA approval for its oral combination anticancer drug TAS-102 (trifluridine hydrochloride) for refractory metastatic colorectal cancer (mCRC), which is marketed in Japan under the brand name Lonsurf.
